FEB 22-23 2017 Opens: 6:00 AM PT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Precision Medicine 2017
5 43 3226

LabRoots' exciting free virtual event – Precision Medicine 2016 - was a success! So much so that we would like to include Precision Medicine into our line-up for 2017.

Imagine receiving a full diagnosis from a simple blood test, or the ability to tailor the perfect treatment to your individual genetic makeup, taking into account your specific susceptibilities to side effects. What if we could apply a patient’s genetic information to gain insights into the genetic variations of diseases and expedite drug development, to create more precise therapies? This is the goal of Precision Medicine.
Learn more about the 2016 inaugural event by watching this video.

Precision Medicine 2017 will continue the dialogue and provide updates on the Precision Medicine Initiative ® (PMI), that called for initial funding of $215 million to support the creation of a national research cohort of 1 million or more U.S. volunteers (the PMI Cohort Program; $130 million), new efforts in cancer drug development ($70 million), advances in FDA regulatory structures ($10 million), and development of interoperability standards and requirements that address privacy and enable secure exchange of data across systems through the ONC ($5 million).
Precision Medicine is becoming an integral part of research in the science community. The discipline not only involves individual genetic information, but also environmental, behavioral, and clinical data. A combination of these factors allows researchers to put together a comprehensive view of each patient that aids in their search for precision approaches to health maintenance, disease prevention, and therapies.

We are proud to include C&EN as our partner in this virtual event. 

Continuing Education
By participating in this virtual event and watching webcast presentations, you can earn Free Continuing Education (CE) and/or Continuing Medical Education (CME) credits. To earn educational credits, you must view an entire presentation. Following the presentation you must click on the educational credit link provided for that particular speaker and follow the required process. Once you have completed the process, you will receive a certificate for the educational credit.

Use #LRprecisionmed to follow the conversation
 


Speakers:
  • Biologist, Biosystems & Biomaterials Division
  • Head of the Pharmacogenetics Research Clinic at the Campbell Family Mental Health Research Institute at CAMH, and Associate Professor in the Department of Psychiatry at the University of Toronto
  • Professor and Consultant at Mayo Clinic
  • Founder and Chairman at Cancer Commons
  • Clinical Head, Healthy Genome Initiatives, Staff Genetic Counselor, Applied Genomics
  • President and Chief Executive Officer Centrose
  • Assistant Professor of Pediatrics Institute for Computational Health Sciences University of California, San Francisco
  • Head of Knowledge Systems, Marie-Josée & Henry R. Kravis Center for Molecular Oncology
  • Director of the Translational Genomics Core of Partners HealthCare Personalized Medicine, Harvard Medical School
  • Director, Medical Metagenomics Texas Children's Microbiome Center Texas Children's Hospital Assistant Professor Baylor College of Medicine
  • Director, Genomic Medicine Institute Geisinger Health System
  • Director of the Center for Data Driven Discovery in Biomedicine (D3b) Director for Neurosurgical Translational Research, Division of Neurosurgery Director of Children's Brain Tumor Tissue Consortium in Neurosurgery (CBTTC)
  • Head, Genetics at GlaxoSmithKline
  • President and Chief Executive Officer, Metabolon
  • President and CEO at Biocept

Show Resources
Agenda
All times are Pacific Time
  • FEB 22, 2017 06:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    GenomeFIRST ™ A new paradigm for the return of genomic results
    Speaker: Marc Williams, MD
  • FEB 22, 2017 06:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Integrating genomics platforms and data in Biobanks
    Speaker: Sami Amr, PhD
  • FEB 22, 2017 06:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Mate-pair next generation sequencing as a powerful clinical tool for the characterization of cancer
    Speaker: David Smith, PhD
  • FEB 22, 2017 10:30 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Beyond the hype: the evidence behind the role of genetics in drug response
    Speaker: Matt Nelson, PhD
  • FEB 22, 2017 10:30 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Clinical Whole Genome Sequencing In a Healthy Population
    Speaker: Erica Ramos, MS, CGC
  • FEB 22, 2017 10:30 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Towards a new era of precision medicine in psychiatry: Using genetic algorithms to optimize medication outcome
    Speaker: Daniel Mueller, PhD
  • FEB 22, 2017 12:00 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Measurement Assurance for Tissue Engineering & Regenerative Medicine
    Speaker: Carl Simon, PhD
  • FEB 23, 2017 06:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Title Coming Soon
    Speaker: Michael Nall
  • FEB 23, 2017 10:30 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Metabolomics and its Role in Precision Medicine
    Speaker: John Ryals, PhD
  • FEB 23, 2017 10:30 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Rapid Learning for Precision Oncology
    Speaker: Marty Tenenbaum, PhD
  • FEB 23, 2017 12:00 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Novel Precision medicines that exploit Proximity
    Speaker: James Prudent, PhD
  • Clinical Implementations of Precision Medicine
  • FEB 22, 2017 06:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    GenomeFIRST ™ A new paradigm for the return of genomic results
    Speaker: Marc Williams, MD
  • FEB 22, 2017 10:30 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Clinical Whole Genome Sequencing In a Healthy Population
    Speaker: Erica Ramos, MS, CGC
  • FEB 22, 2017 10:30 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Towards a new era of precision medicine in psychiatry: Using genetic algorithms to optimize medication outcome
    Speaker: Daniel Mueller, PhD
  • How Advancements are Shaping Precision Medicine
  • FEB 22, 2017 06:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Integrating genomics platforms and data in Biobanks
    Speaker: Sami Amr, PhD
  • FEB 23, 2017 06:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Title Coming Soon
    Speaker: Michael Nall
  • FEB 23, 2017 10:30 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Metabolomics and its Role in Precision Medicine
    Speaker: John Ryals, PhD
  • FEB 22, 2017 06:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Mate-pair next generation sequencing as a powerful clinical tool for the characterization of cancer
    Speaker: David Smith, PhD
  • FEB 23, 2017 10:30 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Rapid Learning for Precision Oncology
    Speaker: Marty Tenenbaum, PhD
  • FEB 23, 2017 12:00 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Novel Precision medicines that exploit Proximity
    Speaker: James Prudent, PhD
  • Precision Medicine for Drug Development
  • FEB 22, 2017 10:30 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Beyond the hype: the evidence behind the role of genetics in drug response
    Speaker: Matt Nelson, PhD
  • Precision Medicine Issues and Challenges
  • FEB 22, 2017 12:00 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Measurement Assurance for Tissue Engineering & Regenerative Medicine
    Speaker: Carl Simon, PhD
Posters

 

POSTER SUBMISSION GUIDELINES

Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer reviewed. Submission is free.

 

SUBMIT YOUR ABSTRACT

Enter the following information to this Submission Form:

  • Poster Title
  • Your Name
  • Your Institution
  • Your Email
  • Abstract describing the poster

 

All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

 

If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster.  LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

 

Questions? Email [email protected]

LabRoots Policy

Speakers

  • Carl Simon, PhD
    Biologist, Biosystems & Biomaterials Division
    Biography
      Dr. Simon is a biologist in the Biomaterials Group at the National Institute of Standards and Technology. We aim to develop reliable tools and standards for measuring the properties of cells, biomaterials, scaffolds and tissue-engineered constructs. As regenerative medicine moves from a research endeavor to a viable industry that benefits patients and U.S. commerce, reliable methods for assessing product consistency and quality are required. In one of our projects, we are working with Kapil Bharti (NIH) to establish simple, robust methods for characterizing tissue-engineered retinal pigment epithelium for use in a clinical trial to treat age-related macular degeneration. In another project, we are working with Pamela Robey (NIH) to improve sampling in measurements of osteogenesis induced by stem cell/scaffold formulations in an ectopic bone mouse model. We also work with computer scientists to develop image analysis and bioinformatics methods for assessing the physical properties of 3D tissue scaffolds and how they influence cell function. Dr. Simon is Chair of ASTM Committee F04.43 "Cells and Tissue-Engineered Constructs" where documentary standards are being developed to support the development of tissue-engineered medical products. He earned a B.S. in Biology from Bucknell University and a Ph.D. in Biochemistry from University of Virginia where his thesis focused on signal transduction during human platelet aggregation. He trained as a post-doctoral fellow in NIST Polymers Division and became a staff scientist at NIST in 2003. Dr. Simon is active in the Society for Biomaterials, ISO, TERMIS and Phacilitate, and is on the editorial board for "Biomaterials" and "Journal of Biomedical Materials Research Part B - Applied Biomaterials".
    • Daniel Mueller, PhD
      Head of the Pharmacogenetics Research Clinic at the Campbell Family Mental Health Research Institute at CAMH, and Associate Professor in the Department of Psychiatry at the University of Toronto
      Biography
        Dr. Mueller earned his MD at the University of Bonn (Germany) and completed his residency training in Psychiatry at the Charité University Clinic in Berlin. In 2008, he has been appointed at the University of Toronto (Department of Psychiatry), and as Clinician Scientist at CAMH. At the same time, he became Head of the Pharmacogenetics Research Clinic at CAMH which is one of the first of its kind worldwide to develop clinical implementation strategies (e.g., Müller DJ et al., 2013; PMID:24151801). Dr. Mueller's overall research goals are to investigate genetic causes of response and side effects to psychiatric medications. This line of research aims to significantly improve treatment of psychiatric conditions and to lessen the burden of medication side effects and to avoid negative drug-drug interactions. In addition, he is actively involved in developing pharmacogenetic guidelines for physicians and patients and is affiliated with the Clinical Pharmacogenetics Implementation Consortium (Caudle et al., 2014; PMID: 24479687). For more information, visit www.pharmacogenetics.ca For a complete publication record, see: https://scholar.google.de/citations?user=lnbto4AAAAAJ&hl=de
      • David Smith, PhD
        Professor and Consultant at Mayo Clinic
        Biography
          David I Smith received his B.S. in Mathematics and Molecular Biology from the University of Wisconsin in Madison. He then received his Ph.D. for the Department of Biochemistry also at the University of Wisconsin in Madison. After several postdoctoral positions he got his first academic appointment at Wayne State University. In 1996 he joined the Mayo Clinic in the Department of Laboratory Medicine and Pathology as Professor and Consultant. He was also appointed as the head of the Cancer Genetics Program for the Mayo Clinic Cancer Center. His research focuses on the role that the common fragile sties play in cancer development. His laboratory also works on the various roles that human papillomavirus plays in the development of different cancers. Dr. Smith is also the Chairman of the Technology Assessment Group for the Mayo Clinic Center for Individualized Medicine. The responsibility of this group is to evaluate new technologies for their potential impact on research and its' clinical translation. His laboratory utilizes next generation sequencing to characterize the molecular alterations that occur during the development of cancer. They also have been using the powerful technique of mate-pair next generation sequencing (MP-Seq) to characterize the physical status of HPV in different HPV-driven cancers.
        • Marty Tenenbaum, PhD
          Founder and Chairman at Cancer Commons
          Biography
            Dr. Jay M. ("Marty") Tenenbaum, a world-renowned Internet commerce pioneer and visionary, founded CommerceNet (1994) to accelerate business use of the Internet. While at CommerceNet, he co-founded Veo Systems (1997), the company that pioneered the use of XML for automating business-to-business transactions. When Commerce One acquired Veo Systems in January 1999, Dr. Tenenbaum became chief scientist and was instrumental in shaping the company's business and technology strategies for the Global Trading Web. Post Commerce One, Dr. Tenenbaum was an officer and director of Webify Solutions (sold to IBM in 2006) and Medstory (sold to Microsoft in 2007). Currently, his focus is on transforming healthcare and accelerating therapy development through collaborative e-science. Towards that end, he founded CollabRx, which builds "virtual biotechs" to help slash the time, cost, and risk of developing new therapies." Prior to CommerceNet, he was founder and CEO of Enterprise Integration Technologies, the first company to conduct a commercial Internet transaction (1992), secure Web transaction (1993), and Internet auction (1993). Earlier in his career, Dr. Tenenbaum was also a prominent AI researcher, and led AI research groups at SRI International and Schlumberger Ltd. Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, and a former consulting professor of Computer Science at Stanford. He currently serves as a director of Efficient Finance, Patients Like Me, and the Public Library of Science, and is a consulting professor of Information Technology at Carnegie Mellon's new West coast campus. Dr. Tenenbaum holds B.S. and M.S. degrees in Electrical Engineering from MIT, and a Ph.D. from Stanford.
          • Erica Ramos, MS, CGC
            Clinical Head, Healthy Genome Initiatives, Staff Genetic Counselor, Applied Genomics
            Biography
              Erica Ramos, MS, LCGC is the Clinical Head for Illumina's "Healthy Genome Initiatives" team and President-Elect for the National Society of Genetic Counselors, the leading professional organization for genetic counselors more than 3500 members strong. After 11 years in patient care, Ms. Ramos joined Illumina in the Clinical Services Laboratory, where she managed the clinical group that implemented interpretation and reporting processes for clinical whole genome sequencing (cWGS). Currently, she focuses on advancing the use of cWGS by providing access and education to healthy individuals through the Understand Your Genome program, MyGenome visualization software and other collaborations. Her focus on education extends to genetic counseling students and she is an Adjunct Professor in the Genetic Counseling Department at Augustana University. She also tweets from @ERamosSD about genomics and genetic counseling, music, travel and other interests.
            • James Prudent, PhD
              President and Chief Executive Officer Centrose
              Biography
                Currently, Dr James Prudent serves as the Chief Executive Officer and Chairman of the Board at CENTROSE, a biotechnology company focused on developing precision therapies for diseases with high unmet need. While exploring interesting natural products, Dr. Prudent and his colleagues discovered that the "all powerful" Na,K-ATPase was interacting with multiple proteins at the cell surface. The biology of the various interacting proteins indicated an evolutionary pattern of energy regulation coupled to growth, motility, and survival. This discovery led to the invention of EDC Technology which allows for the unprecedented precise delivery of drugs. Currently the company has discovered multiple EDCs for cancer and autoimmune disease. Prior to CENTROSE, Dr. Prudent served as Chief Science Officer and Board Member at EraGen Biosciences (now Luminex) where he invented GENE-CODE and MULTI-CODE, technologies that incorporate an expanded genetic code into real-time and multiplexed diagnostic assays. Before EraGen, Dr. Prudent invented Invader Technology while at Third Wave (now Hologic). Invader is complimentary to PCR but does not amplify DNA; making Invader more accurate and easier to use. Today, Invader is being used by Hologic and Exact Sciences in their diagnostic products. Prior to Third Wave, Dr. Prudent received his Ph.D. in Chemistry at the UC - Berkeley under the direction of Professor Peter G. Schultz and his B.S. in Bacteriology and Medical Microbiology at the University of Wisconsin - Madison. He has over 100 publications, patents and patent applications. He is a recipient of the Frost and Sullivan Product of the Year Award and Biotechnology Industry Organization Innovation Award.
              • Dexter Hadley, MD, PhD
                Assistant Professor of Pediatrics Institute for Computational Health Sciences University of California, San Francisco
                Biography
                  Dr. Hadley's expertise is in translating big data into precision medicine and digital health. His work has resulted in an ongoing precision medicine clinical trial for ADHD (ClinicalTrials.gov Identifier: NCT02286817) for a first-in-class, non-stimulant neuromodulator to be targeted across the neuropsychiatric disease spectrum. His laboratory was recently funded by the NIH Big Data to Knowledge initiative to integrate multiple large-scale open databases to allow cross platform computational analyzes powerful enough to discover the functional genes and their related biological pathways that are defective in disease. He received the inaugural UCSF Marcus Award for Precision Medicine to develop a digital health initiative to use smartphones to screen for skin cancer and reduce the mortality of melanoma. In general, the end point of his work is rapid proofs of concept clinical trials in humans that translate into better patient outcomes and reduced morbidity and mortality across the spectrum of disease.
                • Nikolaus Schultz, PhD
                  Head of Knowledge Systems, Marie-Josée & Henry R. Kravis Center for Molecular Oncology
                  Biography
                    Nikolaus Schultz leads the development of the cBioPortal for Cancer Genomics, a popular resource for the visualization and analysis of large-scale cancer genomics data sets. His research focuses on identifying the genomic alterations that underlie different types of cancer. He is involved in several projects of The Cancer Genome Atlas (TCGA) and is an investigator in the Stand Up To Cancer (SU2C) Prostate Cancer Dream Team. Dr. Schultz is an Associate Attending Computational Oncologist in the Department of Epidemiology and Biostatistics and an affiliate member of the Human Oncology and Pathogenesis Program. He is the Head of Knowledge Systems in the Marie-Josée and Henry R. Kravis Center for Molecular Oncology.
                  • Sami Amr, PhD
                    Director of the Translational Genomics Core of Partners HealthCare Personalized Medicine, Harvard Medical School
                    Biography
                      Sami Amr is the Director of the Translational Genomics Core of Partners HealthCare Personalized Medicine where he feels privileged to work with basic and translational researchers across Partners Healthcare to identify DNA, RNA, and methylation markers and signatures of disease that can help de-convolute underlying mechanisms of pathogenesis as well as be leveraged in diagnostic and clinical assays.
                    • Ruth Luna, PhD, MB (ASCP) CM
                      Director, Medical Metagenomics Texas Children's Microbiome Center Texas Children's Hospital Assistant Professor Baylor College of Medicine
                      Biography
                        Dr. Luna focuses on research and development of real-time PCR and next generation sequencing technologies for application in microbial metagenomics. Dr. Luna holds an interest in clinical study design as well as correlation of shifts in the microbiome with changes in disease state. She is also involved in a collaborative study regarding molecular epidemiology in the cystic fibrosis population of Texas Children's Hospital. Dr. Luna serves as Director of the DNA Sequencing Core of the Texas Children's Microbiome Center.
                      • Marc Williams, MD
                        Director, Genomic Medicine Institute Geisinger Health System
                        Biography
                          My primary interest has been to study the impact of implementing genetics, genomics and family history in routine clinical care. Successful implementation requires the application of many disparate elements including technology assessment, modeling and decision analysis, the science of behavioral change, quality improvement, knowledge management, informatics, health care economics and patient-centered outcomes all of which are components of the emerging discipline of implementation science. I am also very interested in defining the value proposition of new genomic technologies with value being simplistically represented as outcomes/cost. My research to date has examined the impact of family history on provider experience; the role of informatics to provide point-of-care, "just-in-time" education resources and passive decision support to clinicians regarding genetic topics; impact of tumor-based screening for Lynch syndrome (including extensive modeling to optimize the efficiency of the program); use of query tools to obtain information on genetic conditions from electronic data warehouses; and application of the tools of quality improvement to facilitate implementation of evidence-based best practices in genetics and genomics. I am now beginning to explore how we can get information from patients about their preferences including an assessment of the patient's location on the State of Change continuum and use those preferences to reconcile priorities regarding preventive and therapeutic interventions with the patient's provider to see if that will improve satisfaction for both and increase compliance with recommendations leading to measurable improvement in outcomes and improved value.
                        • Adam Resnick PhD
                          Director of the Center for Data Driven Discovery in Biomedicine (D3b) Director for Neurosurgical Translational Research, Division of Neurosurgery Director of Children's Brain Tumor Tissue Consortium in Neurosurgery (CBTTC)
                          Biography
                            Biography Coming Soon
                          • Matt Nelson, PhD
                            Head, Genetics at GlaxoSmithKline
                            Biography
                              Matt Nelson is the head of Genetics at GSK, working in Philadelphia, PA, leading a group of scientists to bring genetic evidence into both drug discovery and drug development decisions. Research activities of interest include investigating the role of growing body genome-wide association studies to inform drug target selection and validation, improving pharmacogenetics experiment design and developing methods and strategies for drawing inferences from both small- and large-scale genetic association studies. Other recent activities include analysis of deep resequence data for target validation, development of the POPRES genetic resource for pharmacogenetics research and co-chair of the scientific management committee of the cross-industry International Serious Adverse Event Consortium (iSAEC). Matt's path to research in the pharmaceutical industry began at the University of Michigan, where he received degrees in statistics and human genetics with an emphasis on novel combinatorial strategies for identifying gene-by-gene interaction. Upon graduation, he worked with start-up biopharmaceutical company Esperion Therapeutics for three years. At Esperion, his activities included cheminformatics, preclinical and clinical study design and analysis, development of online analysis and reporting tools, and leading the information systems group. Matt joined Sequenom, a San Diego-based biotechnology company, in early 2002 as director of biostatistics, where he was involved in some of the earliest attempts at genome-wide association studies. Matt has been with GSK since 2005 with prior roles as researcher and head of Statistical Genetics.
                            • John Ryals, PhD
                              President and Chief Executive Officer, Metabolon
                              Biography
                                Dr. John Ryals co-founded Metabolon, Inc. in 2002 and serves as president and CEO. Metabolon is a pioneer and leader in the field of metabolomics and its use in precision medicine and human health. Prior to Metabolon, he was a co-founder, CEO and president of Paradigm Genetics, Inc., a publicly traded agricultural biotechnology company focused on industrializing the process of gene function discovery. Dr. Ryals has 30 years' experience in the biotechnology industry, including senior research positions at Novartis and Ciba-Geigy. He currently serves on the board of directors at AgBiome, a provider of early-stage R&D for agriculture, and the advisory board of the College of Agriculture and Life Sciences at North Carolina State University. He earned a B.A. in biology and chemistry from the University of North Texas and M.S. and Ph.D. degrees in molecular biology from the University of Texas at Dallas.
                              • Michael Nall
                                President and CEO at Biocept
                                Biography
                                  Mr. Nall has over 25 years of healthcare sales and marketing experience, most recently serving at Clarient Diagnostic Services, Inc. in positions of increasing responsibility from 2002 through August 2013, with his last position being General Manager, North American Sales and Marketing. While at Clarient, Mr. Nall was also responsible for leading the team assimilating Clarient into GE Healthcare after Clarient was acquired in 2010. From 1988 until joining Clarient, Mr. Nall served in the diagnostic and medical device industries in various commercial leadership roles for companies including Impath, American Cyanamid, Maquet Surgical, Strato Medical, Horizon Medical Products and Columbia Vital Systems. Mr. Nall received a Bachelor of Science degree in Business Administration from Central Missouri State University (now known as the University of Central Missouri).
                                Sponsors

                                For information on becoming a sponsor or exhibitor, please click here.


                                Committee

                                To download the Program Committee brochure here.


                                • Sarah Elsea, PhD

                                  Dr. Sarah H. Elsea is an Associate Professor of Molecular and Human Genetics at Baylor College of Medicine and is Senior Division Director of Biochemical Genetics at Baylor Genetics. Dr. Elsea earned a B.S. in chemistry from Missouri State University and Ph.D. in biochemistry ...

                                  Show more Show less
                                • Iya Khalil, PhD

                                  Iya Khalil, co-founder and executive vice president of GNS, has promoted use of the Cambridge, MA-based company's technology in the biopharma industry. One of the inventors of the company's computational platform, her work has helped major players such as Biogen Idec and Johnson ...

                                  Show more Show less
                                • Tatjana Matejic, PhD, D(ABMLI)

                                • Giacinto Scoles, PhD

                                  Giacinto Scoles (b. 1935, married to Lim Giok Lan since 1964) is Donner professor of Science, Emeritus at Princeton University, distinguished adjoint professor in the Departments of Physics and Biology at Temple University, and distinguished scientist at Synchrotron Elettra in ...

                                  Show more Show less
                                Help

                                General LabRoots Questions

                                For bugs, spam, technical support or questions please call +1-714-463-4673 or email [email protected]  
                                Contact us

                                Virtual Events and Webinars

                                Supported Configurations

                                • Operating System Internet Explorer Firefox Chrome Safari
                                  Vista IE8+ FF10+ Chrome15+
                                  Windows 7 IE8+ FF10+ Chrome15+
                                  Windows 8 IE10 FF10+ Chrome15+
                                  Mac OS X   FF10+ Chrome15+ Safari5.1+
                                • Cookie settings: session cookies enabled
                                • Browser configuration must have JavaScript enabled
                                • Adobe Flash player 10.2 or later

                                To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                Internet Connection

                                • A minimum of 100Kbps is recommended for audio-only events
                                • A minimum of 300Kbps is recommended for speaker on-video events

                                Computer Equipment

                                • Screen Resolution: Minimum 1024x768
                                • Video Card: 65,000 colors minimum
                                • Sound card and speakers (or headphones) for hearing webcast in full format
                                • Audio Card: 16-bit minimum
                                • RAM: 512MB of free RAM

                                Firewall Protocol

                                • HTTP on port 80 or HTTPS on port 443
                                • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                Work-At-Home Attendees

                                • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                For A Seamless Experience

                                When using a mobile device, FREE Mobile Apps are available:

                                - For viewing Webinars:

                                - For viewing Virtual Events

                                Attendee Guide

                                • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                Virtual Event and Webinar Support:

                                Continuing Education (CME/CE) Support

                                Loading Comments...
                                Show Resources
                                Event Countdown
                                • 0 Days
                                • 0 Hours
                                • 0 Minutes
                                • 0 Seconds